FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/02/2024
Back to search
Official data from USPTO
ALENTIS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ALENTIS
ST13
US500000079338873Class
5, 42, 44
Filing
79338873
Registration
7341501
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
11/02/2024
Trademark type
Word
Nice classes
5, 42, 44
Filing date
02/07/2022
Registration date
04/02/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/02/2024
Last transaction
04/02/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
25
Owner location
CH
Examiner
ANKRAH, NAAKWAMA S
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Alentis Therapeutics AG
Representatives
Dermot J. Horgan IpHorgan Ltd.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical productsfor the treatment of cancerautoimmune diseasesorgan fibrosis; chemical preparations for pharmaceutical or medical purposesfor the treatment of cancerautoimmune diseasesorgan fibrosis; biological preparations for medical and therapeutic use for the treatment of cancerautoimmune diseasesorgan fibrosis; all the aforesaid goods not for ophthalmological use; biopharmaceutical productspharmaceutical preparations for cancer treatment; pharmaceutical preparations and substances for cancer treatment; pharmaceutical preparations and substances for cancer prevention
Class 42
Scientific and medical research and development in the field of fibrosisautoimmune diseasescancer; biotechnological research services in the field of fibrosisautoimmune diseasescancer; providing scientific research information in the pharmaceutical and biomedical field; scientific research for medical purposes in the field of cancerous diseases; scientific advice relating to medicine
Class 44
Medical analysis services for diagnosing cancer; RNA or DNA analysis for cancer diagnosis and prognosis; provision of medical information in the field of cancer preventionscreeningdiagnosis and treatment; medical advice and information regarding pharmaceutical and medical products; medical testing
Publications
History of USPTO decisions and trademark events.
32 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/16/2024
FIMP
FINAL DISPOSITION PROCESSED
10/16/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/03/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/02/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/16/2024
PUBO
PUBLISHED FOR OPPOSITION
01/16/2024
GPNX
NOTIFICATION PROCESSED BY IB
01/13/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/27/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/27/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/27/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/31/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
10/21/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/27/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/27/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/27/2023
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
04/27/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/26/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/26/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/26/2023
RFNT
REFUSAL PROCESSED BY IB
02/14/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/26/2023
RFRR
REFUSAL PROCESSED BY MPU
01/26/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/23/2022
CNRT
NON-FINAL ACTION WRITTEN
11/22/2022
DOCK
ASSIGNED TO EXAMINER
11/19/2022
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
11/10/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
07/16/2022
MAFR
APPLICATION FILING RECEIPT MAILED
04/26/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/22/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/21/2022
Continuous trademark protection
Get notified about every new filing that threatens ALENTIS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.